Cargando…

Tildrakizumab in the treatment of psoriasis – literature review

Psoriasis is a chronic, inflammatory disease. The incidence of its occurrence in developed countries is 1–4%. The aim of this study is to present the current state of knowledge and characterize the antibody tildrakizumab, which in March 2018 was approved by the FDA agency for use in adult patients w...

Descripción completa

Detalles Bibliográficos
Autor principal: Banaszczyk, Katarzyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753595/
https://www.ncbi.nlm.nih.gov/pubmed/31548750
http://dx.doi.org/10.5114/reum.2019.87620